Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis

Area of Science:

• Immunology
• Infectious Diseases
• Pulmonology

Background:

• Current tuberculosis (TB) treatment requires at least 6 months.
• Immune adjuvant therapy with recombinant interferon-gamma1b (rIFN-gamma1b) may reduce pulmonary inflammation and infectivity.
• rIFN-gamma1b may promote earlier sputum clearance.

Purpose of the Study:

• To evaluate the efficacy of rIFN-gamma1b as an adjuvant therapy for pulmonary tuberculosis.
• To assess the impact of nebulized or subcutaneous rIFN-gamma1b on inflammatory cytokines, immune response, and sputum clearance.
• To determine the effect of rIFN-gamma1b on constitutional symptoms in TB patients.

Main Methods:

• Randomized, controlled clinical trial involving 89 patients with cavitary pulmonary tuberculosis.
• Directly Observed Therapy, Short-course (DOTS) alone versus DOTS supplemented with nebulized or subcutaneous rIFN-gamma1b for 4 months.
• Bronchoalveolar lavage (BAL) and blood sampling at baseline and 4 months; assessment of inflammatory cytokines, CD4+ lymphocyte response, sputum Mtb clearance, and constitutional symptoms.

Main Results:

• Nebulized rIFN-gamma1b significantly reduced inflammatory cytokines (IL-1beta, IL-6, IL-8, IL-10) in BAL fluid.
• Both rIFN-gamma1b groups showed increased CD4+ lymphocyte response to PPD.
• Nebulized rIFN-gamma1b significantly improved sputum smear Mtb clearance at 4 weeks and reduced fever, wheeze, and night sweats.

Conclusions:

• rIFN-gamma1b adjuvant therapy combined with DOTS can reduce local inflammation in pulmonary tuberculosis.
• This therapy enhances sputum Mtb clearance and improves constitutional symptoms.
• Nebulized rIFN-gamma1b shows promise in shortening treatment duration and improving patient outcomes.